We identified anti-GM-CSF autoantibodies as the cause of disseminated nocardiosis in a previously healthy and apparently immunocompetent adult. This case emphasizes the importance of including ACA in the differential diagnosis of PID, especially in previously healthy adults. Importantly, anti-GM-CSF ...
TABLE 2. Anti-GM-CSF autoantibody screeninga SampleRLU value(s) IFN-γIL-17AAnti-GM-CSFautoantibodies Healthy control (n = 4) 217 ± 263 367 ± 461 59 ± 46 Positive control 18,085 12,850.5 5,397.5 Patient 733.8 731.3 4,711.3 a Screening of patient plasma for interferon gamma (INF...
including the anti–desmoglein 3 autoantibodies of pemphigus vulgaris,9 the anti-acetylcholine or anti-muscle–specific kinase autoantibodies of myasthenia gravis,10,11 the anti–GM-CSF autoantibodies of pulmonary alveolar proteinosis,12 and the anti-erythropoietin autoantibodies of pure red cell aplasia....
Granulocyte–macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF; also known as CSF1), granulocyte colony-stimulating factor (G-CSF) and interleukin-3 (IL-3) can each play a part in the host response to injury and infection, and there is burgeoning inte...
However, a role for complement is not demonstrated in MG associated with other autoantibodies. Anti-muscle-specific kinase antibodies, for example, are of the IgG4 isotype which do not bind complement [29]. As such, complement directed treatment trials have only included AChR Ab positive patients...
CSF testing Anti-Sj/ITPR1 has been identified from serum samples. Whether ITPR1 enters the CNS exclusively from the periphery or is also produced intrathecally is currently unknown. So far, testing of serum samples is recommended. However, given that many autoantibodies in neurological disease are...
Anti-Abeta autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. Front Neurol. 2015;6:207. Article PubMed PubMed Central Google Scholar Pichler M, Vemuri P, Rabinstein AA, Aakre J, Flemming ...
In 1999, high titers of neutralizing anti-GM-CSF autoantibodies were reported in patients with late-onset PAP, which accounts for 90% of PAP cases [6]. Moreover, the pathogenic role of anti-GM-CSF autoantibodies was demonstrated in experimental conditions and in a non-human primate model, ...
months post-treatment. In contrast to PAP, SLE patients are, however, not characterized by anti-GM-CSF autoantibodies. The similar results obtained in the studies from Kavuru et al. and Vallerskog et al. therefore rather suggest that the combination of an anti-CD20 and anti-GM-CSF antibody ...
angiostatin or endostatin, or, a biological response modifier such as a lymphokine, interleukin-1 (IL-1), interleukin-2 (IL-2), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), nerve growth factor (NGF) or other growth factor and ...